Related Experiment Videos
Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector
Federico Mingozzi1, Jörg Schüttrumpf, Valder R Arruda
1Department of Pediatrics, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA.
Journal of Virology
|September 20, 2002
Summary
Adeno-associated viral vector serotype 5 (AAV-5) significantly enhances gene transfer efficiency and factor IX expression in hepatocytes compared to AAV-2. This AAV-5 vector shows improved transduction rates and broader expression in liver tissue for potential hemophilia B treatments.
Area of Science:
- Hepatology
- Gene Therapy
- Viral Vector Technology
Background:
- Adeno-associated viral (AAV) vectors are promising for stable gene transfer in hepatocytes.
- AAV vectors are being explored for treating inherited liver disorders like hemophilia B.
Purpose of the Study:
- To compare the efficacy of AAV serotype 2 (AAV-2) and AAV serotype 5 (AAV-5) vectors for gene transfer in hepatocytes.
- To evaluate the potential of AAV-5 for enhanced expression of coagulation factor IX (F.IX).
Main Methods:
- In vivo administration of AAV-2 and AAV-5 vectors.
- Assessment of hepatocyte transduction efficiency.
- Quantification of F.IX transgene expression levels.
Main Results:
- AAV-5 vectors demonstrated a 3- to 10-fold increase in F.IX transgene expression compared to AAV-2.
- AAV-5 transduced a higher proportion of hepatocytes (approximately 15%) than AAV-2.
- AAV-5 mediated broader transgene expression throughout the liver parenchyma.
Conclusions:
- AAV-5 is a superior vector for hepatocyte gene transfer and F.IX expression compared to AAV-2.
- AAV-5 holds significant potential for improving gene therapy strategies for hemophilia B.
- Enhanced transduction efficiency and expression area of AAV-5 support its clinical development.